SCHEMBL561065

SCHEMBL561065

O=C(Nc1c(F)cccc1Cl)c1ccn(Cc2ccccc2Oc2ccccc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
LMNA P02545 6/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
STAT3 P40763 1/20 0.47
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPK8 P45983 2/20 0.43
NPSR1 Q6W5P4 4/20 0.42
HTT P42858 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL561619 0.94 SMN1; SMN2 (0.46) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL562253 0.90 RAB9A (0.45) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL561303 0.89 SMN1; SMN2 (0.48) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL561357 0.89 SMN1; SMN2 (0.45) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL561263 0.88 SMN1; SMN2 (0.47) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL561638 0.86 NPC1 (0.43) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL561007 0.86 KMT2A (0.51) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL561320 0.86 PTGER1 (0.55) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL561551 0.85 PYGL (0.47) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL562353 0.84 NPC1 (0.51) NPC1RAB9AMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035237-A1 PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS COE DIANE MARY (GB) 2012-02-09 US disclosed
US-20120035237-A1 PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS COE DIANE MARY (GB) 2012-02-09 US disclosed
US-20120035237-A1 PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS COE DIANE MARY (GB) 2012-02-09 US disclosed
WO-2010122088-A1 PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035237-A1 PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS RYR2, PAICS, CTRC NPC1 2163/4885RAB9A 1294/4885MEN1 4118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.